Our study of CY as a prototype of DNA/HDAC dual-targeting drug demonstrates that by incorporating HDAC inhibitory moiety into traditional DNA-damaging drugs, it is indeed possible to achieve much higher toxicity against cancer cells. This evidence concerns the gene HDAC9 and cancer.